|Synonyms||SKL-N05, ADX-N05, ARL-N05, YKP10A, R228060, and JZP-110; (R)-2-amino-3-phenylpropylcarbamate hydrochloride|
|Elimination half-life||~7.1 h|
|Excretion||urine (95% unchanged)|
|Chemical and physical data|
|Molar mass||194.234 g/mol g·mol−1|
|3D model (JSmol)|
Common side effects include headache, nausea, anxiety, and trouble sleeping. It is a norepinephrine–dopamine reuptake inhibitor (NDRI). It is derived from phenylalanine and its chemical name is (R)-2-amino-3-phenylpropylcarbamate hydrochloride.
The drug was discovered by a subsidiary of SK Group, which licensed rights outside of 11 countries in Asia to Aerial Pharma in 2011. Aerial ran two Phase II trials of the drug in narcolepsy before selling the license to solriamfetol to Jazz in 2014; Jazz Pharmaceuticals paid Aerial $125 million up front and will pay Aerial and SK up to $272 million in milestone payments, and will pay double digit royalties to SK.
In March 2019 the FDA accepted SK's and Jazz' NDA for use of solriamfetol to treat excessive sleepiness in people with narcolepsy or obstructive sleep apnea; the drug has an orphan designation for narcolepsy.
During development it has been called SKL-N05, ADX-N05, ARL-N05, and JZP-110.
Solriamfetol had also been tested in animal models of depression, but as of 2017 that work had not been advanced to clinical trials.